MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Molecular Subtyping of Salivary Adenoid Cystic Carcinomas Enhances Prognostic Precision

MedXY Editorial Team•Oct 13, 2026•news
Adenoid Cystic Carcinomacopy number variationmolecular subtypesprognostic biomarkers

Introduction

Adenoid cystic carcinoma (ACC) is a rare malignancy predominantly affecting salivary glands, characterized by heterogeneous histopathologic features including tubular, cribriform, and solid components. ACC is known for its indolent yet relentless clinical course marked by frequent local recurrences, perineural invasion, and late distant metastases. Despite pathological classifications developed over decades, challenges persist in establishing standardized grading systems due to the morphological complexity and coexistence of different histologic patterns within single tumors.

The lack of robust, reliable prognostic biomarkers further complicates management strategies, necessitating novel molecular tools to augment clinical pathological assessment. The study by Liu et al. addresses this unmet need by performing comprehensive genomic and transcriptomic profiling of ACC to delineate molecular subtypes associated with clinical outcomes.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Predicting Outcomes in Advanced Systemic Mastocytosis with KIT Inhibitors: Insights from Genetic and Laboratory MonitoringThis article reviews how genetic profiling and dynamic laboratory markers predict clinical outcomes in advanced systemic mastocytosis treated with KIT inhibitors avapritinib and midostaurin, facilitating optimized treatment strategies.Oct 23, 2026Decoding the Genomic and Clinical Impact of RAS Mutations in Acute Myeloid LeukemiaThis comprehensive analysis of 8,553 AML patients reveals diverse RAS mutation patterns, their associations with other genomic alterations, and distinct prognostic implications influenced by the genomic context and treatment modalities, guiOct 22, 2026Molecular Subtypes in Transthyretin Cardiac Amyloidosis: Insights from Proteomics Profiling and Tafamidis EfficacyComprehensive plasma proteomics reveal three molecular subtypes of transthyretin cardiac amyloidosis linked to distinct prognoses and differential tafamidis treatment responses, highlighting personalized therapeutic opportunities.Sep 13, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
TP53 Mutations in Acute Myeloid Leukemia: Impact on Outcomes Post-Allogeneic Hematopoietic Cell Transplantation
TP53 mutations define a high-risk AML subset with inferior survival post-allo-HCT, driven mainly by relapse. Molecular heterogeneity may guide personalized post-transplant strategies.
Sep 10, 2026
Molecular Subtypes of Uterine Leiomyomas: Clinical Implications and MRI-Based Predictive Triage in a Large Retrospective CohortThis study analyzes 720 genotyped uterine leiomyomas, revealing distinct clinical behaviors and treatment responses across molecular subtypes, with MRI aiding prognostic stratification to inform surgical and pharmacologic management.Sep 7, 2026
Decoding the Tumor Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic Insights from CD163 and CD11c ProfilingThis study identifies distinct tumor immune microenvironment subgroups in diffuse large B-cell lymphoma based on CD163 and CD11c expression, revealing prognostic significance and potential therapeutic stratification with checkpoint inhibitoAug 11, 2026